Загрузка...
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Cancer immunotherapy by targeting of immune checkpoint molecules has been a research ‘hot-spot' in recent years. Nivolumab, a human monoclonal antibody targeting PD-1, has been widely used clinically since 2014. However, the binding mechanism of nivolumab to PD-1 has not yet been shown, despite...
Сохранить в:
| Опубликовано в: : | Nat Commun |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5303876/ https://ncbi.nlm.nih.gov/pubmed/28165004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms14369 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|